On November 4, 2024, Mark Hahn, the Chief Financial Officer of Verona Pharma PLC (VRNA, Financial), sold 129,672 shares of the company. The transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 14,293,736 shares of Verona Pharma PLC.
Verona Pharma PLC is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for the treatment of respiratory diseases. The company's focus includes products aimed at treating conditions such as chronic obstructive pulmonary disease and cystic fibrosis.
Over the past year, the insider has sold a total of 1,800,000 shares and has not made any purchases. The recent sale is part of a broader trend observed over the past year, where there have been 12 insider sells and only 3 insider buys within the company.
Shares of Verona Pharma PLC were trading at $4.38 on the day of the sale, giving the company a market cap of approximately $3.14 billion. This valuation reflects the company's standing and investor expectations based on its financial performance and growth prospects.
The following image shows the trend in insider transactions for Verona Pharma PLC over the past year:
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors and analysts can visit the respective links.
This insider sale might be of interest to investors tracking insider behaviors as an indicator of confidence levels regarding the company's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
